Planek/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focused on the discovery and development of T cell immunotherapies for solid tumors, today announced that it has filed three patent applications with the European Patent Office, underscoring Medigene's commitment to advancing T cell-based immunotherapies for the treatment of solid tumors.
Interferon gamma (IFNγ) biosensor
The first patent application is for our innovative interferon gamma (IFNγ) biosensor, a technology that monitors and quantifies IFNγ release from cytokine-secreting cells in real time. This unique technology allows for a deeper understanding of immune response dynamics through a simplified and efficient cytometric detection method. The IFNγ biosensor technology overcomes the limitations of currently available commercial tools, which are often costly, time-consuming and error-prone with complex procedures that reduce reproducibility. Furthermore, traditional methods typically only allow endpoint measurements and do not support long-term, real-time monitoring of IFNγ, which the use of this IFNγ biosensor makes possible.
High-precision TCR tracking (UniTope and TraCR)
In addition, Medigene has applied for two patents related to its novel T cell receptor (TCR)-specific antigen-antibody binding technology. UniTope and TraCRThe technology incorporates two tools designed to uniquely tag the TCR and precisely track its location, allowing research subjects to precisely assess the proliferation, persistence and localization of TCR-guided cell therapies. In vitro or In vivoThis will provide important insight into the efficacy and mechanisms of cell therapy.
“The patent application filed with the European Patent Office further sheds light on our unique scientific and technological approach as we incorporate new proprietary technologies to further enhance our end-to-end (E2E) platform,” said Selwyn Ho, CEO of MediGene. “These innovative tools will enable MediGene to increase overall efficiency in the development of best-in-class TCRs and TCR-based therapeutics, increasing reproducibility in measuring safety and efficacy parameters from earlier in the development process, significantly reducing time and costs.”
Medigene is continually expanding and enhancing its patent portfolio with new technologies and extending existing patents to other jurisdictions. The company maintains over 20 different patent families worldwide covering applications protecting Medigene's 3S (Sensitivity, Specificity, Safety) TCR and proprietary E2E platform technology.
— End of press release —
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company focused on developing differentiated T cell therapies for the treatment of solid tumors. The company's end-to-end platform is built on multiple unique and proprietary technologies that enable the company to generate optimal T cell receptors against both cancer-testis antigens and neoantigens, enrich and potentiate these T cell receptor modified (TCR)-T cells to create best-in-class differentiated TCR-T therapies, and optimize drug formulations for safety, efficacy, and durability. The end-to-end platform delivers product candidates to both its own therapeutic pipeline and to partnerings. Medigene's lead TCR-T program, MDG1015, is expected to file for IND in Q3 2024 and CTA in Q4 2024. For more information, please visit www.medgene.com/. https://medigene.com/
About Medigene's End-to-End Platform
Medigene's immunotherapies help activate patients' own defense mechanisms by harnessing T cells in the fight against cancer. Medigene's end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class differentiated TCR-T therapies. The platform includes multiple TCR generation and optimization technologies (e.g., Allo-HLA (Allo-HLA) TCR priming) and product enhancement technologies (e.g., PD1-41BB and CD40L-CD28 costimulatory switch proteins, iM-TCR) to address the challenges in developing effective, durable and safe TCR-T therapies. Partnerships with multiple companies, including BioNTech and Regeneron, continuously validate the platform's assets and technologies.
This press release contains forward-looking statements that represent Medigene's views as of the date of this press release. The actual results achieved by Medigene may differ materially from the forward-looking statements herein. Medigene assumes no obligation to update these forward-looking statements.® is a registered trademark of Medigene AG. This trademark may be owned or licensed in certain territories only.
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investors@medigene.com
If you do not wish to receive information about Medigene, please contact us by email atinvestors@medigene.comWe will then remove your address from our distribution list.
